Granata Bio launched in 2018 with a mission to invigorate the stagnant US offerings in the US fertility medication marketplace. The company gained immediate traction by designing innovative clinical development programs aimed at optimizing outcomes for study subjects while assessing the safety and efficacy of investigational products. To date, the company has assembled a portfolio of four medications, ranging from commercialized products to early-stage developments.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/28/24 | $14,000,000 | Series A |
Alumni Ventures Group Amboy Street Ventures CooperSurgical Gedeon Richter GV  Vibe Bio | undisclosed |
